<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="Activity\PMC7822064\results\search\disease\results.xml">
  <result pre="Short Communication Thiophen urea derivatives as a new class of" exact="hepatitis" post="C virus entry inhibitors H. C. Ryu et al."/>
  <result pre="properly cited.IENZ_36_1870456.pdf Abstract Abstract To develop unique small-molecule inhibitors of" exact="hepatitis" post="C virus (HCV), thiophen urea (TU) derivatives were synthesised"/>
  <result pre="for the development of HCV entry inhibitors. Keywords Entry inhibitor" exact="hepatitis" post="C virus small molecule thiophen urea fig-count: table-count: page-count:"/>
  <result pre="Introduction Approximately 200 million people worldwide are chronically infected with" exact="hepatitis" post="C virus (HCV). This pathogen is the major cause"/>
  <result pre="virus (HCV). This pathogen is the major cause of acute" exact="hepatitis" post="and chronic liver disease, including cirrhosis and liver cancer1."/>
  <result pre="pathogen is the major cause of acute hepatitis and chronic" exact="liver disease," post="including cirrhosis and liver cancer1. HCV is an enveloped,"/>
  <result pre="major cause of acute hepatitis and chronic liver disease, including" exact="cirrhosis" post="and liver cancer1. HCV is an enveloped, positive-stranded RNA"/>
  <result pre="viruses implicated in human disease, such as dengue virus and" exact="yellow fever" post="virus2. Seven major HCV genotypes and numerous subtypes have"/>
  <result pre="reported by the author(s). References References 1LavanchyD.The global burden of" exact="hepatitis" post="C. Liver Int2009;29:74â€&quot;81. 2LindenbachBD, RiceCM.Unravelling hepatitis C virus replication"/>
  <result pre="1LavanchyD.The global burden of hepatitis C. Liver Int2009;29:74â€&quot;81. 2LindenbachBD, RiceCM.Unravelling" exact="hepatitis" post="C virus replication from genome to function. Nature2005;436:933â€&quot;8.16107832 3Van"/>
  <result pre="et al.Consensus proposals for a unified system of nomenclature of" exact="hepatitis" post="C virus genotypes. Hepatology2005;42:962â€&quot;73.16149085 5SulkowskiMS, CooperC, HunyadyB, et al.Management"/>
  <result pre="al.Management of adverse effects of Peg-IFN and ribavirin therapy for" exact="hepatitis" post="C. Nat Rev Gastroenterol Hepatol2011;8:212â€&quot;23.21386812 6ZajÄ…cM, MuszalskaI, SobczakA, et"/>
  <result pre="7ElHefnawiMM, ZadaS, El-AzabIA.Prediction of prognostic biomarkers for interferon-based therapy to" exact="hepatitis" post="C virus patients: a meta-analysis of the NS5A protein"/>
  <result pre="8AghemoA, DegasperiE, ColomboM.Directly acting antivirals for the treatment of chronic" exact="hepatitis" post="C: unresolved topics from registration trials. Dig Liver Dis2013;45:1â€&quot;7.22695478"/>
  <result pre="Natl Acad Sci USA2017;114:E2136â€&quot;45.28232513 17HungTC, JasseyA, LiuCH, et al.Berberine inhibits" exact="hepatitis" post="C virus entry by targeting the viral E2 glycoprotein."/>
  <result pre="al.A central hydrophobic E1 region controls the pH range of" exact="hepatitis" post="C virus membrane fusion and susceptibility to fusion inhibitors."/>
  <result pre="fusion inhibitors. J Hepatol2019;70:1082â€&quot;92.30769006 19MaCD, ImamuraM, TalleyDC, et al.Fluoxazolevir inhibits" exact="hepatitis" post="C virus infection in humanized chimeric mice by blocking"/>
  <result pre="Microbiol2020;5:1532â€&quot;41.32868923 20HuZ, RoltA, HuX, et al.Chlorcyclizine inhibits viral fusion of" exact="hepatitis" post="C virus entry by directly targeting HCV envelope glycoprotein"/>
  <result pre="1. Cell Chem Biol2020;27:780â€&quot;92.e5.32386595 21TongY, LavilletteD, LiQ, et al.Role of" exact="hepatitis" post="C virus envelope glycoprotein E1 in virus entry and"/>
 </snippets>
</snippetsTree>
